{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:43:49Z","timestamp":1762508629529,"version":"3.37.3"},"reference-count":94,"publisher":"Bentham Science Publishers Ltd.","issue":"15","funder":[{"DOI":"10.13039\/501100003141","name":"CONACyT-M\u00e9xico","doi-asserted-by":"publisher","award":["283144","377873","6379"],"award-info":[{"award-number":["283144","377873","6379"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2022,5]]},"abstract":"\nBackground:<\/jats:title>\nThe major hurdles for successful cancer treatment are drug resistance\nand invasiveness developed by breast cancer stem cells (BCSC).<\/jats:p>\n<\/jats:sec>\n\nObjective:<\/jats:title>\nAs these two processes are highly energy-dependent, the identification of the\nmain ATP supplier required for stem cell viability may result advantageous in the design\nof new therapeutic strategies to deter malignant carcinomas.<\/jats:p>\n<\/jats:sec>\n\nMethods:<\/jats:title>\nThe energy metabolism (glycolysis and oxidative phosphorylation, OxPhos)\nwas systematically analyzed by assessing relevant protein contents, enzyme activities,\nand pathway fluxes in BCSC. Once identified as the main ATP supplier, selective energy\ninhibitors and canonical breast cancer drugs were used to block stem cell viability and\nmetastatic properties.<\/jats:p>\n<\/jats:sec>\n\nResults:<\/jats:title>\nOxPhos and glycolytic protein contents, as well as HK and LDH activities were\nseveral times higher in BCSC than in their parental line, MCF-7 cells. However, CS,\nGDH, COX activities, and both energy metabolism pathway fluxes were significantly\nlower (38-86%) in BCSC than in MCF-7 cells. OxPhos was the main ATP provider\n(>85%) in BCSC. Accordingly, oligomycin (a specific and potent canonical OxPhos inhibitor)\nand other non-canonical drugs with inhibitory effect on OxPhos (celecoxib,\ndimethylcelecoxib) significantly decreased BCSC viability, levels of epithelial-mesenchymal\ntransition proteins, invasiveness, and induced ROS over-production, with IC50 values\nranging from 1 to 20 \u03bcM in 24 h treatment. In contrast, glycolytic inhibitors (gossypol, iodoacetic\nacid, 3-bromopyruvate, 2-deoxyglucose) and canonical chemotherapeutic drugs\n(paclitaxel, doxorubicin, cisplatin) were much less effective against BCSC viability\n(IC50> 100 \u03bcM).<\/jats:p>\n<\/jats:sec>\n\nConclusion:<\/jats:title>\nThese results indicated that the use of some NSAIDs may be a promising alternative\ntherapeutic strategy to target BCSC.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867328666211005124015","type":"journal-article","created":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T10:15:03Z","timestamp":1634984103000},"page":"2719-2735","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Celecoxib and Dimethylcelecoxib Block Oxidative Phosphorylation,\nEpithelial-Mesenchymal Transition and Invasiveness in Breast Cancer\nStem Cells"],"prefix":"10.2174","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1688-3878","authenticated-orcid":true,"given":"Juan Carlos","family":"Gallardo-P\u00e9rez","sequence":"first","affiliation":[{"name":"Departamento de Bioqu\u00edmica, Instituto Nacional de Cardiolog\u00eda, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8073-421X","authenticated-orcid":true,"given":"Alhel\u00ed Ad\u00e1n-Ladr\u00f3n","family":"de Guevara","sequence":"additional","affiliation":[{"name":"Departamento de Bioqu\u00edmica, Instituto Nacional de Cardiolog\u00eda, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4403-5363","authenticated-orcid":true,"given":"Marco Antonio","family":"Garc\u00eda-Amezcua","sequence":"additional","affiliation":[{"name":"Departamento de Bioqu\u00edmica, Instituto Nacional de Cardiolog\u00eda, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7287-938X","authenticated-orcid":true,"given":"Diana Xochiquetzal","family":"Robledo-Cadena","sequence":"additional","affiliation":[{"name":"Departamento de Bioqu\u00edmica, Instituto Nacional de Cardiolog\u00eda, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6772-6389","authenticated-orcid":true,"given":"Silvia Cecilia","family":"Pacheco-Vel\u00e1zquez","sequence":"additional","affiliation":[{"name":"Departamento de Bioqu\u00edmica, Instituto Nacional de Cardiolog\u00eda, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0125-0223","authenticated-orcid":true,"given":"Javier Alejandro","family":"Belmont-D\u00edaz","sequence":"additional","affiliation":[{"name":"Departamento de Bioqu\u00edmica, Instituto Nacional de Cardiolog\u00eda, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3484-4124","authenticated-orcid":true,"given":"Jorge Luis","family":"Vargas-Navarro","sequence":"additional","affiliation":[{"name":"Departamento de Bioqu\u00edmica, Instituto Nacional de Cardiolog\u00eda, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9587-7184","authenticated-orcid":true,"given":"Rafael","family":"Moreno-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Departamento de Bioqu\u00edmica, Instituto Nacional de Cardiolog\u00eda, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0822-1233","authenticated-orcid":true,"given":"Sara","family":"Rodr\u00edguez-Enr\u00edquez","sequence":"additional","affiliation":[{"name":"Departamento de Bioqu\u00edmica, Instituto Nacional de Cardiolog\u00eda, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev.med.56.062804.103324","volume":"56","author":"Osborne C.","year":"2005","unstructured":"Osborne C.; Tripathy D.; Aromatase inhibitors: rationale and use in breast cancer. Annu Rev Med 2005,56,103-116","journal-title":"Annu Rev Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4137\/BCBCR.S29420","volume":"9","author":"Nounou M.I.","year":"2015","unstructured":"Nounou M.I.; ElAmrawy F.; Ahmed N.; Abdelraouf K.; Goda S.; Syed-Sha-Qhattal H.; Breast cancer: conventional diagnosis and treatment modalities and recent patents and technologies. Breast Cancer (Auckl) 2015,9(Suppl. 2),17-34","journal-title":"Breast Cancer (Auckl)"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"Waks A.G.","year":"2019","unstructured":"Waks A.G.; Winer E.P.; Breast cancer treatment: A review. JAMA 2019,321(3),288-300","journal-title":"JAMA"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1186\/bcr1982","volume":"10","author":"Fillmore C.M.","year":"2008","unstructured":"Fillmore C.M.; Kuperwasser C.; Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008,10(2),R25","journal-title":"Breast Cancer Res"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1200\/JCO.2008.16.3931","volume":"26","author":"Kakarala M.","year":"2008","unstructured":"Kakarala M.; Wicha M.S.; Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 2008,26(17),2813-2820","journal-title":"J Clin Oncol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3390\/cancers30100716","volume":"3","author":"Kong D.","year":"2011","unstructured":"Kong D.; Li Y.; Wang Z.; Sarkar F.H.; Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: Are they cousins or twins? Cancers (Basel) 2011,3(1),716-729","journal-title":"Cancers (Basel)"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1158\/1055-9965.EPI-13-0785","volume":"23","author":"Mimeault M.","year":"2014","unstructured":"Mimeault M.; Batra S.K.; Molecular biomarkers of cancer stem\/progenitor cells associated with progression, metastases, and treatment resistance of aggressive cancers. Cancer Epidemiol Biomarkers Prev 2014,23(2),234-254","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"5506","DOI":"10.1158\/0008-5472.CAN-05-0626","volume":"65","author":"Ponti D.","year":"2005","unstructured":"Ponti D.; Costa A.; Zaffaroni N.; Pratesi G.; Petrangolini G.; Coradini D.; Pilotti S.; Pierotti M.A.; Daidone M.G.; Isolation and in vitro propagation of tumorigenic breast cancer cells with stem\/progenitor cell properties. Cancer Res 2005,65(13),5506-5511","journal-title":"Cancer Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.semcancer.2014.06.004","volume":"31","author":"Cojoc M.","year":"2015","unstructured":"Cojoc M.; Mäbert K.; Muders M.H.; Dubrovska A.; A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms. Semin Cancer Biol 2015,31,16-27","journal-title":"Semin Cancer Biol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.biocel.2015.06.010","volume":"65","author":"Rodríguez-Enríquez S.","year":"2015","unstructured":"Rodríguez-Enríquez S.; Hernández-Esquivel L.; Marín-Hernández A.; El Hafidi M.; Gallardo-Pérez J.C.; Hernández-Reséndiz I.; Rodríguez-Zavala J.S.; Pacheco-Velázquez S.C.; Moreno-Sánchez R.; Mitochondrial free fatty acid β-oxidation supports oxidative phosphorylation and proliferation in cancer cells. Int J Biochem Cell Biol 2015,65,209-221","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.bcp.2018.05.013","volume":"154","author":"Pritchard R.","year":"2018","unstructured":"Pritchard R.; Rodríguez-Enríquez S.; Pacheco-Velázquez S.C.; Bortnik V.; Moreno-Sánchez R.; Ralph S.; Celecoxib inhibits mitochondrial O consumption, promoting ROS dependent death of murine and human metastatic cancer cells via the apoptotic signalling pathway. Biochem Pharmacol 2018,154,318-334","journal-title":"Biochem Pharmacol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1021\/acs.molpharmaceut.8b00015","volume":"15","author":"Pacheco-Velázquez S.C.","year":"2018","unstructured":"Pacheco-Velázquez S.C.; Robledo-Cadena D.X.; Hernández-Reséndiz I.; Gallardo-Pérez J.C.; Moreno-Sánchez R.; Rodríguez-Enríquez S.; Energy metabolism drugs block triple negative breast metastatic cancer cell phenotype. Mol Pharm 2018,15(6),2151-2164","journal-title":"Mol Pharm"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/ph13120463","volume":"13","author":"Robledo-Cadena D.X.","year":"2020","unstructured":"Robledo-Cadena D.X.; Gallardo-Pérez J.C.; Dávila-Borja V.; Pacheco-Velázquez S.C.; Belmont-Díaz J.A.; Ralph S.J.; Blanco-Carpintero B.A.; Moreno-Sánchez R.; Rodríguez-Enríquez S.; Non-steroidal anti-inflammatory drugs increase cisplatin, paclitaxel, and doxorubicin efficacy against human cervix cancer cells. Pharmaceuticals (Basel) 2020,13(12),463","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"11029","DOI":"10.18632\/oncotarget.2789","volume":"5","author":"Lamb R.","year":"2014","unstructured":"Lamb R.; Harrison H.; Hulit J.; Smith D.L.; Lisanti M.P.; Sotgia F.; Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1\/2 inhibition. Oncotarget 2014,5(22),11029-11037","journal-title":"Oncotarget"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.18632\/oncotarget.2010","volume":"5","author":"Pastò A.","year":"2014","unstructured":"Pastò A.; Bellio C.; Pilotto G.; Ciminale V.; Silic-Benussi M.; Guzzo G.; Rasola A.; Frasson C.; Nardo G.; Zulato E.; Nicoletto M.O.; Manicone M.; Indraccolo S.; Amadori A.; Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation. Oncotarget 2014,5(12),4305-4319","journal-title":"Oncotarget"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10549-014-3051-2","volume":"146","author":"Vlashi E.","year":"2014","unstructured":"Vlashi E.; Lagadec C.; Vergnes L.; Reue K.; Frohnen P.; Chan M.; Alhiyari Y.; Dratver M.B.; Pajonk F.; Metabolic differences in breast cancer stem cells and differentiated progeny. Breast Cancer Res Treat 2014,146(3),525-534","journal-title":"Breast Cancer Res Treat"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"14777","DOI":"10.18632\/oncotarget.4401","volume":"6","author":"De Luca A.","year":"2015","unstructured":"De Luca A.; Fiorillo M.; Peiris-Pagès M.; Ozsvari B.; Smith D.L.; Sanchez-Alvarez R.; Martinez-Outschoorn U.E.; Cappello A.R.; Pezzi V.; Lisanti M.P.; Sotgia F.; Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells. Oncotarget 2015,6(17),14777-14795","journal-title":"Oncotarget"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"32843","DOI":"10.1074\/jbc.M111.260935","volume":"286","author":"Zhou Y.","year":"2011","unstructured":"Zhou Y.; Zhou Y.; Shingu T.; Feng L.; Chen Z.; Ogasawara M.; Keating M.J.; Kondo S.; Huang P.; Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis. J Biol Chem 2011,286(37),32843-32853","journal-title":"J Biol Chem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jprot.2013.06.027","volume":"91","author":"Emmink B.L.","year":"2013","unstructured":"Emmink B.L.; Verheem A.; Van Houdt W.J.; Steller E.J.; Govaert K.M.; Pham T.V.; Piersma S.R.; Borel Rinkes I.H.; Jimenez C.R.; Kranenburg O.; The secretome of colon cancer stem cells contains drug-metabolizing enzymes. J Proteomics 2013,91,84-96","journal-title":"J Proteomics"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"e1336","DOI":"10.1038\/cddis.2014.285","volume":"5","author":"Ciavardelli D.","year":"2014","unstructured":"Ciavardelli D.; Rossi C.; Barcaroli D.; Volpe S.; Consalvo A.; Zucchelli M.; De Cola A.; Scavo E.; Carollo R.; D\u2019Agostino D.; Forlì F.; D\u2019Aguanno S.; Todaro M.; Stassi G.; Di Ilio C.; De Laurenzi V.; Urbani A.; Breast cancer stem cells rely on fermentative glycolysis and are sensitive to 2-deoxyglucose treatment. Cell Death Dis 2014,5,e1336","journal-title":"Cell Death Dis"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/jcb.24671","volume":"115","author":"Palorini R.","year":"2014","unstructured":"Palorini R.; Votta G.; Balestrieri C.; Monestiroli A.; Olivieri S.; Vento R.; Chiaradonna F.; Energy metabolism characterization of a novel cancer stem cell-like line 3AB-OS. J Cell Biochem 2014,115(2),368-379","journal-title":"J Cell Biochem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.4161\/15384101.2014.974419","volume":"14","author":"Shen Y.A.","year":"2015","unstructured":"Shen Y.A.; Wang C.Y.; Hsieh Y.T.; Chen Y.J.; Wei Y.H.; Metabolic reprogramming orchestrates cancer stem cell properties in nasopharyngeal carcinoma. Cell Cycle 2015,14(1),86-98","journal-title":"Cell Cycle"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/j.1476-5381.2010.00743.x","volume":"160","author":"Ford L.A.","year":"2010","unstructured":"Ford L.A.; Roelofs A.J.; Anavi-Goffer S.; Mowat L.; Simpson D.G.; Irving A.J.; Rogers M.J.; Rajnicek A.M.; Ross R.A.; A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br J Pharmacol 2010,160(3),762-771","journal-title":"Br J Pharmacol"},{"key":"ref=24","first-page":"3118","volume":"40","author":"Brinkley B.R.","year":"1980","unstructured":"Brinkley B.R.; Beall P.T.; Wible L.J.; Mace M.L.; Turner D.S.; Cailleau R.M.; Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro. Cancer Res 1980,40(9),3118-3129","journal-title":"Cancer Res"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.bbamcr.2017.06.015","volume":"1864","author":"Gallardo-Pérez J.C.","year":"2017","unstructured":"Gallardo-Pérez J.C.; Adán-Ladrón de Guevara A.; Marín-Hernández A.; Moreno-Sánchez R.; Rodríguez-Enríquez S.; HPI\/AMF inhibition halts the development of the aggressive phenotype of breast cancer stem cells. Biochim Biophys Acta Mol Cell Res 2017,1864(10),1679-1690","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s00204-012-0809-3","volume":"86","author":"Marín-Hernández A.","year":"2012","unstructured":"Marín-Hernández A.; Gallardo-Pérez J.C.; López-Ramírez S.Y.; García-García J.D.; Rodríguez-Zavala J.S.; Ruiz-Ramírez L.; Gracia-Mora I.; Zentella-Dehesa A.; Sosa-Garrocho M.; Macías-Silva M.; Moreno-Sánchez R.; Rodríguez-Enríquez S.; Casiopeina II-gly and bromo-pyruvate inhibition of tumor hexokinase, glycolysis, and oxidative phosphorylation. Arch Toxicol 2012,86(5),753-766","journal-title":"Arch Toxicol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1016\/j.bbamcr.2015.09.033","volume":"1853","author":"Hernández-Reséndiz I.","year":"2015","unstructured":"Hernández-Reséndiz I.; Román-Rosales A.; García-Villa E.; López-Macay A.; Pineda E.; Saavedra E.; Gallardo-Pérez J.C.; Alvarez-Ríos E.; Gariglio P.; Moreno-Sánchez R.; Rodríguez-Enríquez S.; Dual regulation of energy metabolism by p53 in human cervix and breast cancer cells. Biochim Biophys Acta 2015,1853(12),3266-3278","journal-title":"Biochim Biophys Acta"},{"key":"ref=28","first-page":"5702","volume":"44","author":"Nakashima R.A.","year":"1984","unstructured":"Nakashima R.A.; Paggi M.G.; Pedersen P.L.; Contributions of glycolysis and oxidative phosphorylation to adenosine 5\u2032-triphosphate production in AS-30D hepatoma cells. Cancer Res 1984,44(12 Pt 1),5702-5706","journal-title":"Cancer Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.biocel.2010.07.010","volume":"42","author":"Rodríguez-Enríquez S.","year":"2010","unstructured":"Rodríguez-Enríquez S.; Carreño-Fuentes L.; Gallardo-Pérez J.C.; Saavedra E.; Quezada H.; Vega A.; Marín-Hernández A.; Olín-Sandoval V.; Torres-Márquez M.E.; Moreno-Sánchez R.; Oxidative phosphorylation is impaired by prolonged hypoxia in breast and possibly in cervix carcinoma. Int J Biochem Cell Biol 2010,42(10),1744-1751","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/jcp.25617","volume":"232","author":"Marín-Hernández Á.","year":"2017","unstructured":"Marín-Hernández Á.; Gallardo-Pérez J.C.; Hernández-Reséndiz I.; Del Mazo-Monsalvo I.; Robledo-Cadena D.X.; Moreno-Sánchez R.; Rodríguez-Enríquez S.; Hypoglycemia enhances epithelial-mesenchymal transition and invasiveness, and restrains the Warburg phenotype, in hypoxic HeLa cell cultures and microspheroids. J Cell Physiol 2017,232(6),1346-1359","journal-title":"J Cell Physiol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.31557\/APJCP.2018.19.11.3175","volume":"19","author":"Isnaini I.","year":"2018","unstructured":"Isnaini I.; Permatasari N.; Mintaroem K.; Prihardina B.; Widodo M.A.; Oxidants-Antioxidants Profile in the Breast Cancer Cell Line MCF-7. Asian Pac J Cancer Prev 2018,19(11),3175-3178","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.taap.2019.03.008","volume":"370","author":"Rodríguez-Enríquez S.","year":"2019","unstructured":"Rodríguez-Enríquez S.; Pacheco-Velázquez S.C.; Marín-Hernández Á.; Gallardo-Pérez J.C.; Robledo-Cadena D.X.; Hernández-Reséndiz I.; García-García J.D.; Belmont-Díaz J.; López-Marure R.; Hernández-Esquivel L.; Sánchez-Thomas R.; Moreno-Sánchez R.; Resveratrol inhibits cancer cell proliferation by impairing oxidative phosphorylation and inducing oxidative stress. Toxicol Appl Pharmacol 2019,370,65-77","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref=33","first-page":"25","volume":"28","author":"Plumb J.A.","year":"1999","unstructured":"Plumb J.A.; Cell sensitivity assays : the MTT assay. Methods Mol Med 1999,28,25-30","journal-title":"Methods Mol Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/nmeth.3137","volume":"11","author":"Krzywinski M.","year":"2014","unstructured":"Krzywinski M.; Altman N.; Blainey P.; Points of significance: nested designs. For studies with hierarchical noise sources, use a nested analysis of variance approach. Nat Methods 2014,11(10),977-978","journal-title":"Nat Methods"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.cell.2006.05.036","volume":"126","author":"Bensaad K.","year":"2006","unstructured":"Bensaad K.; Tsuruta A.; Selak M.A.; Vidal M.N.; Nakano K.; Bartrons R.; Gottlieb E.; Vousden K.H.; TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006,126(1),107-120","journal-title":"Cell"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2217\/fon.09.174","volume":"6","author":"Luo Z.","year":"2010","unstructured":"Luo Z.; Zang M.; Guo W.; AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol 2010,6(3),457-470","journal-title":"Future Oncol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/febs.13535","volume":"283","author":"Moreno-Sánchez R.","year":"2016","unstructured":"Moreno-Sánchez R.; Saavedra E.; Gallardo-Pérez J.C.; Rumjanek F.D.; Rodríguez-Enríquez S.; Understanding the cancer cell phenotype beyond the limitations of current omics analyses. FEBS J 2016,283(1),54-73","journal-title":"FEBS J"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/BF01966788","volume":"15","author":"Kramar R.","year":"1984","unstructured":"Kramar R.; Hohenegger M.; Srour A.N.; Khanakah G.; Oligomycin toxicity in intact rats. Agents Actions 1984,15(5-6),660-663","journal-title":"Agents Actions"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12967-017-1315-4","volume":"15","author":"Mikirova N.A.","year":"2017","unstructured":"Mikirova N.A.; Kesari S.; Ichim T.E.; Riordan N.H.; Effect of Infla-Kine supplementation on the gene expression of inflammatory markers in peripheral mononuclear cells and on C-reactive protein in blood. J Transl Med 2017,15(1),213","journal-title":"J Transl Med"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/j.bbabio.2012.05.005","volume":"1817","author":"Rodríguez-Enríquez S.","year":"2012","unstructured":"Rodríguez-Enríquez S.; Hernández-Esquivel L.; Marín-Hernández A.; Dong L.F.; Akporiaye E.T.; Neuzil J.; Ralph S.J.; Moreno-Sánchez R.; Molecular mechanism for the selective impairment of cancer mitochondrial function by a mitochondrially targeted vitamin E analogue. Biochim Biophys Acta 2012,1817(9),1597-1607","journal-title":"Biochim Biophys Acta"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1002\/med.21589","volume":"39","author":"Ralph S.J.","year":"2019","unstructured":"Ralph S.J.; Nozuhur S.; ALHulais R.A.; Rodríguez-Enríquez S.; Moreno-Sánchez R.; Repurposing drugs as pro-oxidant redox modifiers to eliminate cancer stem cells and improve the treatment of advanced stage cancers. Med Res Rev 2019,39(6),2397-2426","journal-title":"Med Res Rev"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.stem.2012.05.007","volume":"10","author":"Visvader J.E.","year":"2012","unstructured":"Visvader J.E.; Lindeman G.J.; Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012,10(6),717-728","journal-title":"Cell Stem Cell"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.3390\/ijms18122574","volume":"18","author":"Prieto-Vila M.","year":"2017","unstructured":"Prieto-Vila M.; Takahashi R.U.; Usuba W.; Kohama I.; Ochiya T.; Drug resistance driven by cancer stem cells and their niche. Int J Mol Sci 2017,18(12),2574","journal-title":"Int J Mol Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.4081\/ejh.2018.2943","volume":"62","author":"Rabinovich I.","year":"2018","unstructured":"Rabinovich I.; Sebastião A.P.M.; Lima R.S.; Urban C.A.; Junior E.S.; Anselmi K.F.; Elifio-Esposito S.; De Noronha L.; Moreno-Amaral A.N.; Cancer stem cell markers ALDH1 and CD44+\/CD24- phenotype and their prognosis impact in invasive ductal carcinoma. Eur J Histochem 2018,62(3),2943","journal-title":"Eur J Histochem"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10911-009-9109-9","volume":"14","author":"Dean M.","year":"2009","unstructured":"Dean M.; ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 2009,14(1),3-9","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"e43726","DOI":"10.1371\/journal.pone.0043726","volume":"7","author":"Bao B.","year":"2012","unstructured":"Bao B.; Ahmad A.; Kong D.; Ali S.; Azmi A.S.; Li Y.; Banerjee S.; Padhye S.; Sarkar F.H.; Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. PLoS One 2012,7(8),e43726","journal-title":"PLoS One"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/nn.3510","volume":"16","author":"Flavahan W.A.","year":"2013","unstructured":"Flavahan W.A.; Wu Q.; Hitomi M.; Rahim N.; Kim Y.; Sloan A.E.; Weil R.J.; Nakano I.; Sarkaria J.N.; Stringer B.W.; Day B.W.; Li M.; Lathia J.D.; Rich J.N.; Hjelmeland A.B.; Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci 2013,16(10),1373-1382","journal-title":"Nat Neurosci"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s12094-011-0656-3","volume":"13","author":"Perona R.","year":"2011","unstructured":"Perona R.; López-Ayllón B.D.; de Castro Carpeño J.; Belda-Iniesta C.; A role for cancer stem cells in drug resistance and metastasis in non-small-cell lung cancer. Clin Transl Oncol 2011,13(5),289-293","journal-title":"Clin Transl Oncol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.pharmthera.2018.02.001","volume":"187","author":"Annett S.","year":"2018","unstructured":"Annett S.; Robson T.; Targeting cancer stem cells in the clinic: Current status and perspectives. Pharmacol Ther 2018,187,13-30","journal-title":"Pharmacol Ther"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"36","DOI":"10.6000\/1929-2279.2013.02.01.7","volume":"2","author":"Naujokat C.","year":"2013","unstructured":"Naujokat C.; Laufer S.; Targeting cancer stem cells with defined compounds and drugs. J Cancer Res Updates 2013,2,36-67","journal-title":"J Cancer Res Updates"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.biocel.2019.01.015","volume":"109","author":"Ghasemi F.","year":"2019","unstructured":"Ghasemi F.; Sarabi P.Z.; Athari S.S.; Esmaeilzadeh A.; Therapeutics strategies against cancer stem cell in breast cancer. Int J Biochem Cell Biol 2019,109,76-81","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1200\/JCO.1999.17.6.1689","volume":"17","author":"Recht A.","year":"1999","unstructured":"Recht A.; Gray R.; Davidson N.E.; Fowble B.L.; Solin L.J.; Cummings F.J.; Falkson G.; Falkson H.C.; Taylor S.G.; Tormey D.C.; Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol 1999,17(6),1689-1700","journal-title":"J Clin Oncol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"2","DOI":"10.5455\/2319-2003.ijbcp000812","volume":"1","author":"Ambili R.","year":"2012","unstructured":"Ambili R.; Toxicities of anticancer drugs and its management. Int J Basic Clin Pharmacol 2012,1,2-12","journal-title":"Int J Basic Clin Pharmacol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s10147-011-0269-4","volume":"17","author":"Horio A.","year":"2012","unstructured":"Horio A.; Fujita T.; Hayashi H.; Hattori M.; Kondou N.; Yamada M.; Adachi E.; Ushio A.; Gondou N.; Sueta A.; Yatabe Y.; Iwata H.; High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers. Int J Clin Oncol 2012,17(2),131-136","journal-title":"Int J Clin Oncol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/S0360-3016(03)00593-5","volume":"57","author":"Woodward W.A.","year":"2003","unstructured":"Woodward W.A.; Strom E.A.; Tucker S.L.; Katz A.; McNeese M.D.; Perkins G.H.; Buzdar A.U.; Hortobagyi G.N.; Hunt K.K.; Sahin A.; Meric F.; Sneige N.; Buchholz T.A.; Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys 2003,57(2),336-344","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nchembio.1712","volume":"11","author":"Weinberg S.E.","year":"2015","unstructured":"Weinberg S.E.; Chandel N.S.; Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol 2015,11(1),9-15","journal-title":"Nat Chem Biol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/mnfr.200700470","volume":"53","author":"Rodríguez-Enríquez S.","year":"2009","unstructured":"Rodríguez-Enríquez S.; Marín-Hernández A.; Gallardo-Pérez J.C.; Carreño-Fuentes L.; Moreno-Sánchez R.; Targeting of cancer energy metabolism. Mol Nutr Food Res 2009,53(1),29-48","journal-title":"Mol Nutr Food Res"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1158\/1078-0432.CCR-17-3070","volume":"24","author":"Ashton T.M.","year":"2018","unstructured":"Ashton T.M.; McKenna W.G.; Kunz-Schughart L.A.; Higgins G.S.; Oxidative phosphorylation as an emerging target in cancer therapy. Clin Cancer Res 2018,24(11),2482-2490","journal-title":"Clin Cancer Res"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"14276","DOI":"10.1021\/acs.jmedchem.0c01013","volume":"63","author":"Xu Y.","year":"2020","unstructured":"Xu Y.; Xue D.; Bankhead A.; Neamati N.; Why all the fuss about oxidative phosphorylation (OXPHOS)? J Med Chem 2020,63(23),14276-14307","journal-title":"J Med Chem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.4161\/cc.10.23.18151","volume":"10","author":"Whitaker-Menezes D.","year":"2011","unstructured":"Whitaker-Menezes D.; Martinez-Outschoorn U.E.; Flomenberg N.; Birbe R.C.; Witkiewicz A.K.; Howell A.; Pavlides S.; Tsirigos A.; Ertel A.; Pestell R.G.; Broda P.; Minetti C.; Lisanti M.P.; Sotgia F.; Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: Visualizing the therapeutic effects of metformin in tumor tissue. Cell Cycle 2011,10(23),4047-4064","journal-title":"Cell Cycle"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccr.2012.08.014","volume":"22","author":"Caro P.","year":"2012","unstructured":"Caro P.; Kishan A.U.; Norberg E.; Stanley I.A.; Chapuy B.; Ficarro S.B.; Polak K.; Tondera D.; Gounarides J.; Yin H.; Zhou F.; Green M.R.; Chen L.; Monti S.; Marto J.A.; Shipp M.A.; Danial N.N.; Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell 2012,22(4),547-560","journal-title":"Cancer Cell"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1002\/ijc.29934","volume":"138","author":"Birkenmeier K.","year":"2016","unstructured":"Birkenmeier K.; Dröse S.; Wittig I.; Winkelmann R.; Käfer V.; Döring C.; Hartmann S.; Wenz T.; Reichert A.S.; Brandt U.; Hansmann M.L.; Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma are highly dependent on oxidative phosphorylation. Int J Cancer 2016,138(9),2231-2246","journal-title":"Int J Cancer"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/0471142905.hg1903s63","volume":"19","author":"Barrientos A.","year":"2009","unstructured":"Barrientos A.; Fontanesi F.; Díaz F.; Evaluation of the mitochondrial respiratory chain and oxidative phosphorylation system using polarography and spectrophotometric enzyme assays. Curr Protoc Hum Genet 2009,19,3","journal-title":"Curr Protoc Hum Genet"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/nprot.2012.048","volume":"7","author":"Zhang J.","year":"2012","unstructured":"Zhang J.; Nuebel E.; Wisidagama D.R.; Setoguchi K.; Hong J.S.; Van Horn C.M.; Imam S.S.; Vergnes L.; Malone C.S.; Koehler C.M.; Teitell M.A.; Measuring energy metabolism in cultured cells, including human pluripotent stem cells and differentiated cells. Nat Protoc 2012,7(6),1068-1085","journal-title":"Nat Protoc"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12943-016-0570-y","volume":"16","author":"Al-Dhfyan A.","year":"2017","unstructured":"Al-Dhfyan A.; Alhoshani A.; Korashy H.M.; Aryl hydrocarbon receptor\/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation. Mol Cancer 2017,16(1),14-32","journal-title":"Mol Cancer"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3389\/fphar.2017.00958","volume":"8","author":"Corbet C.","year":"2018","unstructured":"Corbet C.; Stem cell metabolism in cancer and healthy tissues: Pyruvate in the limelight. Front Pharmacol 2018,8,958","journal-title":"Front Pharmacol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1042\/BCJ20170164","volume":"475","author":"De Francesco E.M.","year":"2018","unstructured":"De Francesco E.M.; Sotgia F.; Lisanti M.P.; Cancer stem cells (CSCs): metabolic strategies for their identification and eradication. Biochem J 2018,475(9),1611-1634","journal-title":"Biochem J"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/carcin\/bgq012","volume":"31","author":"Sánchez-Aragó M.","year":"2010","unstructured":"Sánchez-Aragó M.; Chamorro M.; Cuezva J.M.; Selection of cancer cells with repressed mitochondria triggers colon cancer progression. Carcinogenesis 2010,31(4),567-576","journal-title":"Carcinogenesis"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.stem.2010.07.011","volume":"7","author":"Simsek T.","year":"2010","unstructured":"Simsek T.; Kocabas F.; Zheng J.; Deberardinis R.J.; Mahmoud A.I.; Olson E.N.; Schneider J.W.; Zhang C.C.; Sadek H.A.; The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. Cell Stem Cell 2010,7(3),380-390","journal-title":"Cell Stem Cell"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/j.bcp.2011.07.096","volume":"82","author":"Kato T.","year":"2011","unstructured":"Kato T.; Fujino H.; Oyama S.; Kawashima T.; Murayama T.; Indomethacin induces cellular morphological change and migration via epithelial-mesenchymal transition in A549 human lung cancer cells: a novel cyclooxygenase-inhibition-independent effect. Biochem Pharmacol 2011,82(11),1781-1791","journal-title":"Biochem Pharmacol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1093\/carcin\/bgs367","volume":"34","author":"Wang Z.L.","year":"2013","unstructured":"Wang Z.L.; Fan Z.Q.; Jiang H.D.; Qu J.M.; Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling. Carcinogenesis 2013,34(3),638-646","journal-title":"Carcinogenesis"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jss.2015.03.085","volume":"198","author":"Behr C.A.","year":"2015","unstructured":"Behr C.A.; Hesketh A.J.; Barlow M.; Glick R.D.; Symons M.; Steinberg B.M.; Soffer S.Z.; Celecoxib inhibits Ewing sarcoma cell migration via actin modulation. J Surg Res 2015,198(2),424-433","journal-title":"J Surg Res"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.bbamcr.2012.11.013","volume":"1833","author":"Mandujano-Tinoco E.A.","year":"2013","unstructured":"Mandujano-Tinoco E.A.; Gallardo-Pérez J.C.; Marín-Hernández A.; Moreno-Sánchez R.; Rodríguez-Enríquez S.; Anti-mitochondrial therapy in human breast cancer multi-cellular spheroids. Biochim Biophys Acta 2013,1833(3),541-551","journal-title":"Biochim Biophys Acta"},{"key":"ref=74","first-page":"6096","volume":"63","author":"Harris R.E.","year":"2003","unstructured":"Harris R.E.; Chlebowski R.T.; Jackson R.D.; Frid D.J.; Ascenseo J.L.; Anderson G.; Loar A.; Rodabough R.J.; White E.; McTiernan A.; Women's Health Initiative, Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003,63(18),6096-6101","journal-title":"Cancer Res"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/jnci\/djn324","volume":"100","author":"Takkouche B.","year":"2008","unstructured":"Takkouche B.; Regueira-Méndez C.; Etminan M.; Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 2008,100(20),1439-1447","journal-title":"J Natl Cancer Inst"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s10552-010-9579-5","volume":"21","author":"Brasky T.M.","year":"2010","unstructured":"Brasky T.M.; Bonner M.R.; Moysich K.B.; Ambrosone C.B.; Nie J.; Tao M.H.; Edge S.B.; Kallakury B.V.; Marian C.; Trevisan M.; Shields P.G.; Freudenheim J.L.; Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Causes Control 2010,21(9),1503-1512","journal-title":"Cancer Causes Control"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"GS3","DOI":"10.1158\/1538-7445.SABCS17-GS3-03","volume":"78","author":"Coombes R.C.","year":"2018","unstructured":"Coombes R.C.; Tovey H.; Kilburn L.; Mansi J.; Palmieri C.; Bartlett J.; Hicks J.; Makris A.; Evans A.; Loibl S.; A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT \u2013 Randomised European celecoxib trial). Cancer Res 2018,78,GS3","journal-title":"Cancer Res"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s10495-009-0367-1","volume":"14","author":"Seo A.M.","year":"2009","unstructured":"Seo A.M.; Hong S.W.; Shin J.S.; Park I.C.; Hong N.J.; Kim D.J.; Lee W.K.; Lee W.J.; Jin D.H.; Lee M.S.; Sulindac induces apoptotic cell death in susceptible human breast cancer cells through, at least in part, inhibition of IKKbeta. Apoptosis 2009,14(7),913-922","journal-title":"Apoptosis"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1593\/neo.06781","volume":"9","author":"Scheper M.A.","year":"2007","unstructured":"Scheper M.A.; Nikitakis N.G.; Chaisuparat R.; Montaner S.; Sauk J.J.; Sulindac induces apoptosis and inhibits tumor growth in vivo in head and neck squamous cell carcinoma. Neoplasia 2007,9(3),192-199","journal-title":"Neoplasia"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1124\/mol.63.4.870","volume":"63","author":"Hood W.F.","year":"2003","unstructured":"Hood W.F.; Gierse J.K.; Isakson P.C.; Kiefer J.R.; Kurumbail R.G.; Seibert K.; Monahan J.B.; Characterization of celecoxib and valdecoxib binding to cyclooxygenase. Mol Pharmacol 2003,63(4),870-877","journal-title":"Mol Pharmacol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/107327480200902S04","volume":"9","author":"Koki A.T.","year":"2002","unstructured":"Koki A.T.; Masferrer J.L.; Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Contr 2002,9(2)(Suppl.),28-35","journal-title":"Cancer Contr"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cdp.2003.12.005","volume":"28","author":"Kismet K.","year":"2004","unstructured":"Kismet K.; Akay M.T.; Abbasoglu O.; Ercan A.; Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detect Prev 2004,28(2),127-142","journal-title":"Cancer Detect Prev"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1194\/jlr.M042283","volume":"54","author":"Ramer R.","year":"2013","unstructured":"Ramer R.; Walther U.; Borchert P.; Laufer S.; Linnebacher M.; Hinz B.; Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib. J Lipid Res 2013,54(11),3116-3129","journal-title":"J Lipid Res"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"E21","DOI":"10.3171\/foc.2006.20.4.14","volume":"20","author":"Schönthal A.H.","year":"2006","unstructured":"Schönthal A.H.; Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy. Neurosurg Focus 2006,20(4),E21","journal-title":"Neurosurg Focus"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.mam.2010.02.008","volume":"31","author":"Ralph S.J.","year":"2010","unstructured":"Ralph S.J.; Rodríguez-Enríquez S.; Neuzil J.; Saavedra E.; Moreno-Sánchez R.; The causes of cancer revisited: “mitochondrial malignancy” and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy. Mol Aspects Med 2010,31(2),145-170","journal-title":"Mol Aspects Med"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/febs.12086","volume":"280","author":"Moreno-Sánchez R.","year":"2013","unstructured":"Moreno-Sánchez R.; Hernández-Esquivel L.; Rivero-Segura N.A.; Marín-Hernández A.; Neuzil J.; Ralph S.J.; Rodríguez-Enríquez S.; Reactive oxygen species are generated by the respiratory complex II--evidence for lack of contribution of the reverse electron flow in complex I. FEBS J 2013,280(3),927-938","journal-title":"FEBS J"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/jcp.25349","volume":"231","author":"Yang Y.","year":"2016","unstructured":"Yang Y.; Karakhanova S.; Hartwig W.; D\u2019Haese J.G.; Philippov P.P.; Werner J.; Bazhin A.V.; Mitochondria and mitochondrial ROS in cancer: Novel targets for anticancer therapy. J Cell Physiol 2016,231(12),2570-2581","journal-title":"J Cell Physiol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13287-019-1265-2","volume":"10","author":"Wang C.","year":"2019","unstructured":"Wang C.; Shao L.; Pan C.; Ye J.; Ding Z.; Wu J.; Du Q.; Ren Y.; Zhu C.; Elevated level of mitochondrial reactive oxygen species via fatty acid β-oxidation in cancer stem cells promotes cancer metastasis by inducing epithelial-mesenchymal transition. Stem Cell Res Ther 2019,10(1),175","journal-title":"Stem Cell Res Ther"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.addr.2009.01.001","volume":"61","author":"Nishikawa M.","year":"2009","unstructured":"Nishikawa M.; Hashida M.; Takakura Y.; Catalase delivery for inhibiting ROS-mediated tissue injury and tumor metastasis. Adv Drug Deliv Rev 2009,61(4),319-326","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=90","first-page":"1279","volume":"25","author":"Li W.","year":"2011","unstructured":"Li W.; Ma Q.; Li J.; Guo K.; Liu H.; Han L.; Ma G.; Hyperglycemia enhances the invasive and migratory activity of pancreatic cancer cells via hydrogen peroxide. Oncol Rep 2011,25(5),1279-1287","journal-title":"Oncol Rep"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.2741\/1667","volume":"10","author":"Storz P.","year":"2005","unstructured":"Storz P.; Reactive oxygen species in tumor progression. Front Biosci 2005,10,1881-1896","journal-title":"Front Biosci"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.freeradbiomed.2010.09.006","volume":"49","author":"Reuter S.","year":"2010","unstructured":"Reuter S.; Gupta S.C.; Chaturvedi M.M.; Aggarwal B.B.; Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 2010,49(11),1603-1616","journal-title":"Free Radic Biol Med"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3390\/biom9110735","volume":"9","author":"Aggarwal V.","year":"2019","unstructured":"Aggarwal V.; Tuli H.S.; Varol A.; Thakral F.; Yerer M.B.; Sak K.; Varol M.; Jain A.; Khan M.A.; Sethi G.; Role of reactive oxygen species in cancer progression: molecular mechanisms and recent advancements. Biomolecules 2019,9(11),735","journal-title":"Biomolecules"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.jtcvs.2005.07.018","volume":"130","author":"Backhus L.M.","year":"2005","unstructured":"Backhus L.M.; Petasis N.A.; Uddin J.; Schönthal A.H.; Bart R.D.; Lin Y.; Starnes V.A.; Bremner R.M.; Dimethyl celecoxib as a novel non-cyclooxygenase 2 therapy in the treatment of non-small cell lung cancer. J Thorac Cardiovasc Surg 2005,130(5),1406-1412","journal-title":"J Thorac Cardiovasc Surg"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867328666211005124015","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/197005\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867328666211005124015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T05:25:35Z","timestamp":1657171535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/197005\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":94,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867328666211005124015","relation":{},"ISSN":["0929-8673"],"issn-type":[{"type":"print","value":"0929-8673"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-04-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}